Encoded Therapeutics
Founded 2014 Β· 14 known investors
Encoded develops gene therapies for neurological disorders through an integrated platform approach. The company focuses on translating discoveries from research through clinical development and commercialization.
Also known as Encoded Β· Encoded Therapeutics, Inc.
Founders & leadership
Encoded Therapeutics was founded in 2014 by Stephanie Tagliatela.
Investors Β· 14
Also in the syndicate Β· 7
Company profile
researched Aug 2026Encoded Therapeutics, Inc. is a South San Francisco-based biotechnology company developing precision gene therapies for severe neurological and genetic disorders. Its approach centers on engineering the regulatory elements of gene therapy constructs β promoters, enhancers and 3' untranslated regions β so that a transgene is expressed selectively in the disease-relevant cell types, principally in the brain. The company describes its aim as overcoming limitations of first-generation gene therapy by conferring greater gene specificity, cell selectivity and potency.
The lead program, ETX101, targets SCN1A for SCN1A+ Dravet syndrome, a developmental and epileptic encephalopathy that the company states occurs in roughly 1 in 16,000 births worldwide and is most often caused by loss-of-function variants in SCN1A. ETX101 uses cell-selective targeting of GABAergic neurons together with endogenous gene upregulation via an engineered transcription factor, and per the company's pipeline page has reached pivotal stage. Additional programs include ETX301 for post-amputation neuroma pain (target SCN9A/NaV1.7, nociceptor-selective miRNA knockdown, IND-enabling), a preclinical Angelman syndrome program targeting the UBE3A antisense transcript via unsilencing, and a preclinical Alzheimer's disease/tauopathies program using miRNA knockdown of intracellular tau.
The company is described as a fully integrated organization spanning discovery, manufacturing, clinical development and regulatory affairs, with in-house laboratory operations at its South San Francisco headquarters.
Founding story
Kartik Ramamoorthi, Ph.D. and Stephanie Tagliatela are named as co-founders; Ramamoorthi serves as chief executive officer and Tagliatela as chief scientific officer, both also board members. Both conducted doctoral research in molecular and cellular neuroscience at MIT, and Ramamoorthi previously served on the team that launched Voyager Therapeutics. The company's name derives from the epigenetic code that controls when and where genes are expressed.
Business model
Encoded is a clinical-stage therapeutics developer funded by venture and crossover investors; it advances proprietary gene therapy candidates from discovery through clinical development, with stated capabilities to develop and manufacture one-time gene therapies itself. Sources do not describe product revenue or partnering arrangements.
Not described in the sources; the company is a pre-commercial therapeutics developer financed through equity rounds.
Traction
ETX101 received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for SCN1A+ Dravet syndrome (announced July 2020). The pipeline page lists ETX101 at pivotal stage, ETX301 at IND-enabling, and Angelman syndrome and Alzheimer's/tauopathies programs at preclinical stage. In May 2026 the company reported dosing the first patient in a pivotal ETX101 study and presented POLARIS Phase 1/2 clinical data at the ASGCT 2026 Presidential Symposium.
Latest developments
Company news listings dated May 2026 report: presentation of new POLARIS Phase 1/2 clinical data for ETX101 in Dravet syndrome at the ASGCT 2026 Presidential Symposium (May 13, 2026); presentation of new preclinical data on precision vector engineering across neurology programs at ASGCT 2026 (May 12, 2026); and dosing of the first patient in a pivotal study of ETX101 along with broader portfolio progress (May 06, 2026).
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company positions itself as differentiated from current AAV approaches through advanced vector engineering that adds cell-type selectivity, and describes ETX101 as a potential first-in-class, one-time precision gene therapy for SCN1A+ Dravet syndrome. Sources do not name competitors or provide market share data.
Differentiation rests on engineered regulatory elements that restrict transgene expression to targeted cell types (for example GABAergic neurons or nociceptors) while de-targeting tissues such as the dorsal root ganglion, an approach the company contrasts with first-generation gene therapies that offer limited ability to selectively target dysfunctional cell types.
Technology
Encoded's platform screens thousands of naturally occurring human regulatory sequences using genomics-driven, high-throughput next-generation sequencing methods, then applies machine learning to identify motifs driving desired expression patterns. These optimized regulatory elements (promoters, enhancers, 3'UTRs) are combined with payloads that may be protein-coding genes, engineered transcription factors (eTFs) to upregulate endogenous genes, or RNA modulators such as miRNAs for knockdown. Specific capabilities cited include neuron-specific expression, GABAergic cell-selective expression, and 3'UTR elements that de-target expression from the dorsal root ganglion, where transgene expression can cause dose-limiting toxicity. Computational modeling is used alongside NGS screening to optimize payload and regulatory element design within AAV expression cassettes.
Go-to-market
Development is advanced through company-sponsored clinical studies, including the ENVISION observational/natural history study, the POLARIS Phase 1/2 trials and a pivotal study of ETX101. The company engages patient advocacy and the Dravet community and maintains a pre-approval access statement. No commercial products are described in the sources.
Patients with severe neurological disorders and their treating clinicians, initially children with SCN1A+ Dravet syndrome; the pipeline also addresses post-amputation neuroma pain, Angelman syndrome and Alzheimer's disease/tauopathies. The website maintains dedicated sections for the patient community and healthcare professionals.
Geography
Headquarters and laboratory operations are in South San Francisco, California.
History
Per company statements, Encoded was seeded by Venrock, ARCH Venture Partners, Illumina Ventures and Matrix Capital Management. Beginning in 2019 the company recruited experienced gene therapy executives to prepare ETX101 for the clinic. In July 2020 it raised a $135 million Series D and disclosed FDA Orphan Drug and Rare Pediatric Disease designations for ETX101, planning to start the ENVISION observational study in SCN1A+ Dravet syndrome in the second half of 2020 and Phase 1 trials of ETX101 in 2021. By May 2026 the company reported dosing the first patient in a pivotal study of ETX101 and presented POLARIS Phase 1/2 clinical data and new preclinical vector-engineering data at ASGCT 2026.
Risks & controversies
Sources note general gene therapy development risks referenced by the company, including dose-limiting toxicity arising from transgene expression in the dorsal root ganglion, which its de-targeting elements are designed to mitigate. No controversies are reported in the sources.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Founder mafia
3 people who came through Encoded Therapeutics went on to found or lead other companies.
Timeline Β· 5
launches, deals, and filingsEncoded presented new clinical data from the POLARIS Phase 1/2 trials of ETX101 gene therapy in Dravet syndrome.
Encoded presented preclinical data highlighting precision vector engineering across its neurology programs.
Company announced dosing of the first patient in the pivotal study of ETX101 and reported broader portfolio progress.
Series D led by GV (formerly Google Ventures) to fund first clinical trials in SCN1A+ Dravet syndrome and advance the preclinical pipeline; David Schenkein of GV joined the board as an observer.
$135M source β
The FDA granted Orphan Drug Designation and Rare Pediatric Disease Designation to ETX101 for the treatment of SCN1A+ Dravet syndrome.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Encoded Therapeuticsencoded.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Encoded Therapeutics do?
- Encoded Therapeutics develops precision AAV gene therapies for neurological disorders, led by ETX101 for Dravet syndrome.
- Who founded Encoded Therapeutics?
- Encoded Therapeutics was founded by Stephanie Tagliatela in 2014.
- Who are Encoded Therapeutics's investors?
- Encoded Therapeutics's investors include ARCH Venture Partners, BioBrit, GV (Google Ventures), Illumina Ventures, Menlo Ventures, SoftBank Vision Fund, Venrock.